Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Rank in Stocks #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Share Price
$9.60
Last synced: 2025-05-21
Market Cap
$1.08B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade OptiNose, Inc. (OPTN)

Category

P/B ratio for OptiNose, Inc. (OPTN)
P/B ratio as of August 2026 TTM: -2.42
According to OptiNose, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is -2.42. At the end of 2023 the company had a P/B ratio of -25.04.
P/B ratio history for OptiNose, Inc. from 2015 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) -2.42 43.80%
2024 -1.68 -93.29%
2023 -25.04 792.27%
2022 -2.81 -95.58%
2021 -63.45 -114.37%
2020 441.64 369.60%
2019 94.05 201.63%
2018 31.18 -49.24%
2017 61.42 -130.42%
2016 -201.90 -28.02%
2015 -280.48 0.00%
P/B ratio for similar companies or competitors